Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Connect Twitter with Market Wire News

BPMC News and Press Blueprint Medicines Corporation


home / stock / bpmc / bpmc news

RSS
BPMC BPMC Quote BPMC Short BPMC News BPMC Articles BPMC Message Board
  • Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

    Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire -- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE...

    • January 23, 2023 08:00:00 am
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors

    Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors PR Newswire CAMBRIDGE, Mass. , Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai , M.D., to its board of directors. D...

    • January 06, 2023 09:00:00 am
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale

    Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale PR Newswire -- Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of $108 million to $111 million -- ...

    • January 05, 2023 08:00:00 am
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now

    Summary Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline. The price response to these updates hasn't held into the final stages of the year, however. There are multiple inflectio...

    • December 27, 2022 07:02:21 pm
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Zai Labs: Biopharma's Alibaba, But Better

    Summary Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercialization partnerships with foreign entities. Also, the in-house pipeline is set t...

    • December 13, 2022 01:59:46 pm
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint reports long term data for Ayvakit; elenestinib shows promise in phase 1 trial

    Blueprint Medicines ( NASDAQ: BPMC ) reported long term updated of Ayvakit from the PATHFINDER and EXPLORER trials in patients with advanced systemic mastocytosis (SM) and part of 1 of the HARBOR study of elenestinib. Ayvakit is approved in the US. to treat ...

    • December 12, 2022 05:34:51 am
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

    Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis PR Newswire -- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAM...

    • November 22, 2022 04:36:00 pm
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting

    Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting PR Newswire CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acce...

    • November 03, 2022 09:00:00 am
    • |
    • PR Newswire
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint cut to Perform at Baird on slow uptake for cancer therapy

    Oppenheimer downgraded Blueprint Medicines Corporation ( NASDAQ: BPMC ) to Perform from Outperform at Oppenheimer on Wednesday, noting challenges in the rollout of the biotech's cancer therapy Ayvakit. In January 2020, the FDA approved Ayvakit for certain patients with met...

    • November 02, 2022 04:04:36 pm
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
  • Blueprint Medicines  GAAP EPS of -$2.23 beats by $0.28, revenue of $65.97M beats by $22.09M

    Blueprint Medicines press release ( NASDAQ: BPMC ): Q3 GAAP EPS of -$2.23 beats by $0.28 . Revenue of $65.97M (+172.7% Y/Y) beats by $22.09M . GUIDANCE: Blueprint Medicines anticipates it will achieve the high end of previously provided revenue guidance for ful...

    • November 01, 2022 08:40:07 am
    • |
    • SeekingAlpha
    • |
      • BPMC Stock
      • BPMC Quote
      • BPMC Short
      • BPMC News
      • BPMC Articles
      • BPMC Message Board
Next 10
Stock Information

Blueprint Medicines Corporation Company Name:

BPMC Stock Symbol:

NASDAQ Market:

Blueprint Medicines Corporation Website:

Blueprint Medicines Corporation Logo

Get BPMC Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

Connect Twitter with Market Wire News
RECENT BPMC NEWS
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Join us on Telegram

Join us on Telegram

Join the Trending Stocks News on Telegram to get immediate news notifications!

Telegram


Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2023 Market Wire News